NCT05236894

Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population

Examining the Appeal of Nicotine Pouches in Ohio Appalachia

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Ohio State University Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Accepted

Summary

This clinical trial estimates the abuse liability of nicotine pouches with varying nicotine concentrations relative to cigarette smoking in Appalachian, Ohio and Ohio smokers. Nicotine pouches are a novel tobacco product with potential to reduce or increase the harm of tobacco use. Evaluating nicotine pouches abuse liability among smokers in Ohio including the unique demographic of Appalachia may clarify the public health effect of NPs in Appalachian Ohio and across Ohio. Results may inform public health efforts, policy, and clinical care aimed at reducing tobacco-related disparities.

Detailed description

Aim 1: PRIMARY OBJECTIVE: I. To estimate the abuse liability of nicotine pouches (NPs) with varying nicotine concentrations relative to cigarette smoking. SECONDARY OBJECTIVE: I. To clarify the public health effect of NPs in Appalachian Ohio. EXPLORATORY OBJECTIVES: I. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring nicotine pharmacokinetics. II. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring subjective effects. III. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring intentions to use and switch to NPs. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive lower dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3. ARM II: Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3. ARM III: Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3. Aim 2: PRIMARY OBJECTIVE: I. To understand the pharmacokinetic difference between tobacco-derived and synthetic NPs. SECONDARY OBJECTIVE: I. To clarify the public health effect of NPs on adult smokers EXPLORATORY OBJECTIVES: I. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring nicotine pharmacokinetics. II. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring subjective effects. III. To estimate the abuse liability of tobacco-derived vs. synthetic NPs by measuring intentions to use and switch to NPs. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I: Patients receive a 3mg dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3. ARM II: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3. ARM III: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.

Conditions

• Cigarette Smoking-Related Carcinoma

Interventions

Type	Name	Description
BEHAVIORAL	Cigarette Smoking	Smoke preferred brand of cigarette
DRUG	Nicotine Oral Pouch	Given lower dose nicotine pouch
DRUG	Nicotine Oral Pouch	Given higher dose nicotine pouch
OTHER	Questionnaire Administration	Ancillary studies
DRUG	Nicotine Oral Pouch	Given 3mg nicotine pouch (Aim 2)
DRUG	Nicotine Oral Pouch	Given 3mg nicotine pouch (Aim 2)
DRUG	Nicotine Oral Pouch	Given 3mg nicotine pouch (Aim 2)

Timeline

• Start date: 2022-03-01
• Primary completion: 2023-04-18
• Completion: 2023-04-18
• First posted: 2022-02-11
• Last updated: 2024-05-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study